Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid

Prostate

Volumn 68, Issue 9, 2008, Pages 945-954

  Mattsson, Johanna M ^a   Valmu, Leena ^a,b   Laakkonen, Pirjo ^c   Stenman, Ulf Håkan ^a   Koistinen, Hannu ^a,d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FINNISH RED CROSS BLOOD SERVICE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angiogenesis; Endothelial cell; Glycosylation; Prostate cancer; Structure analysis

Indexed keywords

CARBOHYDRATE; PROSTATE SPECIFIC ANTIGEN; SIALIC ACID;

ANION EXCHANGE CHROMATOGRAPHY; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GROWTH; CHEMICAL ANALYSIS; CONCENTRATION RESPONSE; DISULFIDE BOND; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLYCOSYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; SEMINAL PLASMA; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ENDOTHELIAL CELLS; HUMANS; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; PROSTATE-SPECIFIC ANTIGEN; PROTEIN ISOFORMS; SEMEN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; UMBILICAL VEINS;

EID: 44849091712     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20751     Document Type: Article

References (44)

1. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83(10):3166-3170.
2. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004;41(3):265-312.
3. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80(2):281-285.
4. Lilja H, Abrahamsson PA, Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 1989;264(3):1894-1900.
5. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999;9(2):83-93.
6. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51(1):222-226.
7. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37(9):1618-1625.
8. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL, Saedi MS. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50(5):710-714.
9. Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997;158(4):1606-1609.
10. Niemelä P, Lövgren J, Karp M, Lilja H, Pettersson K. Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. Clin Chem 2002;48(8):1257-1264.
11. Espana F, Gilabert J, Estelles A, Romeu A, Aznar J, Cabo A. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991;64(3):309-320.
12. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220(1):45-53.
13. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995;41(11):1567-1573.
14. Leinonen J, Zhang WM, Stenman UH. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996;155(3):1099-1103.
15. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. See comment. J Natl Cancer Inst 1999;91(19):1635- 1640.
16. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999;81(8):1269-1273.
17. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM, Nelson BJ. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003;56(3):212-219.
18. Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis MI. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res 2001;7(6):1533-1538.
19. Abrahamsson PA, Lilja H, Falkmer S, Wadström LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988;12(1):39-46.
20. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, Bjartell A. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 2007;52(6):1670-1679.
21. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000;6(1):160-165.
22. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;6(4):273-286.
23. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-364.
24. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-410.
25. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9(6):653-660.
26. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65(10):3967-3979.
27. Wu P, Stenman UH, Pakkala M, Närvänen A, Leinonen J. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Prostate 2004;58(4):345-353.
28. Denmeade SR, Lou W, Lövgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57(21):4924-4930.
29. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988;107(4):1589-1598.
30. Stenman UH, Paus E, Allard WJ, Andersson I, Andres C, Barnett TR, Becker C, Belenky A, Bellanger L, Pellegrino CM, Bormer OP, Davis G, et al. Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999;20(Suppl 1):1-12.
31. Belanger A, van Halbeek H, Graves HC, Grandbois K, Stamey TA, Huang L, Poppe I, Labrie F. Molecular mass and carbohydrate structure of prostate specific antigen: Studies for establishment of an international PSA standard. Prostate 1995;27(4):187-197.
32. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003;13(6):457-470.
33. Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, Arai Y, Fukuda M. Carbohydrate structure and differential binding of prostate specific antigen to maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 2004;14(8):671-679.
34. Bodi A, Kaslik G, Venekei I, Graf L. Structural determinants of the half-life and cleavage site preference in the autolytic inactivation of chymotrypsin. Eur J Biochem 2001;268(23): 6238-6246.
35. Vailhe B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Invest 2001;81(4):439-452.
36. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, O'Reilly M, Folkman J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998;95(10):5579-5583.
37. Digtyar AV, Pozdnyakova NV, Feldman NB, Lutsenko SV, Severin SE. Endostatin: Current concepts about its biological role and mechanisms of action. Biochemistry (Mosc) 2007;72(3):235-246.
38. Tabruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 2007;355(1):1-5.
39. Wu P, Zhu L, Stenman UH, Leinonen J. Immunopeptidometric assay for enzymatically active prostate-specific antigen. Clin Chem 2004;50(1):125-129.
40. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48(1):1-6.
41. Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR. Substrate specificity of prostate-specific antigen (PSA). Chem Biol 1998;5(9):475-488.
42. Hartshorn MJ. AstexViewer: A visualisation aid for structure-based drug design. J Comput Aided Mol Des 2002;16(12):871-881.
43. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214(2):317-322.
44. Carvalho AL, Sanz L, Barettino D, Romero A, Calvete JJ, Romao MJ. Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: A homologue of human PSA. J Mol Biol 2002;322(2):325-337.